Iridian Asset Management’s TherapeuticsMD TXMD Stock Holding History

Iridian Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,666	Closed	-$62K	–	89
2021 Q3	$62K	Hold	1,666	–	–	﹤0.01%	87
2021 Q2	$99K	Hold	1,666	–	–	﹤0.01%	110
2021 Q1	$112K	Hold	1,666	–	–	﹤0.01%	118
2020 Q4	$101K	Hold	1,666	–	–	﹤0.01%	90
2020 Q3	$132K	Hold	1,666	–	–	﹤0.01%	79
2020 Q2	$104K	Hold	1,666	–	–	﹤0.01%	72
2020 Q1	$88K	Hold	1,666	–	–	﹤0.01%	77
2019 Q4	$202K	Hold	1,666	–	–	﹤0.01%	76
2019 Q3	$302K	Hold	1,666	–	–	﹤0.01%	72
2019 Q2	$217K	Hold	1,666	–	–	﹤0.01%	71
2019 Q1	$406K	Hold	1,666	–	–	0.01%	69
2018 Q4	$317K	Hold	1,666	–	–	﹤0.01%	70
2018 Q3	$546K	Buy	1,666 +289	+21%	+$88.5K	0.01%	69
2018 Q2	$430K	Buy	1,377 +233	+20%	+$71.2K	﹤0.01%	74
2018 Q1	$279K	Buy	+1,144	New	+$321K	﹤0.01%	84

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Iridian Asset Management's TXMD Position: Q4 2021 in Review

Iridian Asset Management sold out of TherapeuticsMD (TXMD) in Q4 2021, closing a stake of 1,666 shares — an estimated $62K sold.

Iridian Asset Management first reported a position in TXMD in Q1 2018 and held it in 15 quarters. The position peaked at $546K in Q3 2018. 131 funds tracked by Wall St. Rank hold TXMD as of Q4 2021.

Iridian Asset Management reported no remaining TherapeuticsMD position as of Q4 2021 after selling out during the quarter.
Iridian Asset Management sold 1,666 TherapeuticsMD shares in Q4 2021, an estimated $62K.
Iridian Asset Management first reported a position in TherapeuticsMD in Q1 2018 and held it in 15 quarters.
Iridian Asset Management's TherapeuticsMD position peaked at $546K in Q3 2018.
131 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2021.

Based on Iridian Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.